Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Amgen, Servier Complete Product Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Amgen, Servier Complete Product Pact

Split up cardiovascular assets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen and Servier have completed their cardiovascular product collaboration agreement from July 8, 2013. Amgen has obtained U.S. commercial rights to Servier’s novel oral drug, approved in the EU as Procoralan (ivabradine) for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier’s investigational molecule, S38844, for cardiovascular diseases in the U.S. S38844 is currently in Phase II development for the treatment of heart failure. Additionally, Servier has obtained an exclusive option to commercialize omecamtiv mecarbil in Europe. Omecamtiv mecarbil is an activator of cardiac myosin, which is currently being studied for the treatment of heart failure in patients with systolic dysfunction.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics